Photo Credit: Sdigital
The following is a summary of “Efficacy and safety of treat-and-extend intravitreal brolucizumab in naive and switched patients with macular neovascularization: one-year follow-up study,” published in the October 2024 issue of Ophthalmology by Faraldi et al.
Researchers conducted a retrospective study to evaluate the efficacy and safety of treat-and-extend (T&E) intravitreal (IV) Brolucizumab in patients with macular neovascularization (MNV).
They analyzed the data from 41 eyes of the 41 patients (20 new and 21 switched), and changes were observed in central subfoveal thickness (CST), fluid presence, best-corrected visual acuity (BCVA), number of injections, and the time between treatments. Patients were administered 3 monthly IV injections, and a T&E regimen based on disease activity.
The results showed a significant decrease in CST (from 412.1 ± 115.8 to 273.2 ± 61.6; P < 0.05) and an improvement in BCVA (mean; P) in the new patients. However, in the switched patients, these parameters remained relatively stable. In the latest and switched groups, 55% and 33.5% of the patients achieved a 12-week interval between injections after 1 year, with an average of 6.55 ± 1 and 7.43 ± 0.68 injections, respectively while only 1 patient experienced mild anterior uveitis without long-term effects.
Investigators concluded that IV Brolucizumab injections, using a T&E regimen, demonstrated strong efficacy and safety, with superior anatomical and functional outcomes in patients with MNV.
Source: bmcophthalmol.biomedcentral.com/articles/10.1186/s12886-024-03706-0
